<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04918082</url>
  </required_header>
  <id_info>
    <org_study_id>20_RIPH3_06</org_study_id>
    <secondary_id>2020-A01290-39</secondary_id>
    <nct_id>NCT04918082</nct_id>
  </id_info>
  <brief_title>Assessment of Quality of Life and Treatment Times for Patients With Invasive Type Breast Cancer in Martinique</brief_title>
  <acronym>Qualibreast-MQ</acronym>
  <official_title>Assessment of Quality of Life and Treatment Times for Patients With Invasive Type Breast Cancer in Martinique</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Center of Martinique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Center of Martinique</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cancer and its treatments can be factors that alter the quality of life of patients. The&#xD;
      induced alteration of the quality of life can influence compliance and impact survival.&#xD;
      Considering the after-effects of the treatment, carrying out such a survey will provide for&#xD;
      the first time precise information on the main determinants of the quality of life as well as&#xD;
      on the care pathway of patients with invasive breast cancer in the Martinique region.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Breast cancer is the second most common cancer in the West Indies and the leading cancer in&#xD;
      women. With 215 new cases in Guadeloupe, 204 in Martinique and 56 in French Guiana each year,&#xD;
      it accounts for 37%, 33% and 26% of incident cancer cases in women respectively, but also&#xD;
      affects men. Its incidence, lower than in France, is increasing over the period 2008-2014.&#xD;
      The diagnostic and therapeutic management of cancer can have an impact on the quality of life&#xD;
      of patients, taking into account the adverse effects occurring during and after treatment,&#xD;
      both in the short and long term. The European Organisation for Research and Treatment of&#xD;
      Cancer (EORTC) has developed a series of questionnaires to assess the quality of life of&#xD;
      cancer patients, including a general questionnaire (QLQ-C30) and specific modules for breast&#xD;
      cancer (EORTC BREAST (EORTC QLQ-BR23)) with the objective of improving professional&#xD;
      practices.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2020</start_date>
  <completion_date type="Anticipated">October 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of global disorders in patients with breast cancer</measure>
    <time_frame>12 months after diagnosis</time_frame>
    <description>Quality of life of patients with invasive breast cancer in Martinique assessed by QLQ-C30</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of disorders specific to breast cancer patients Assessment of disorders specific to breast cancer patients</measure>
    <time_frame>12 months after diagnosis</time_frame>
    <description>Quality of life of patients with invasive breast cancer in Martinique assessed by QLQ-BR23</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of global disorders in patients with breast cancer</measure>
    <time_frame>36 months after diagnosis</time_frame>
    <description>Quality of life of patients with invasive breast cancer in Martinique assessed by QLQ-C30</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of disorders specific to breast cancer patients</measure>
    <time_frame>36 months after diagnosis</time_frame>
    <description>Quality of life of patients with invasive breast cancer in Martinique assessed by QLQ-BR23</description>
  </primary_outcome>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Quality of Life</condition>
  <condition>Survivorship</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality of life questionnaires</intervention_name>
    <description>Patients' quality of life will be assessed with self-reported items through both the EORTC-QLQ-C30 and EORTC-QLQ-BR23 modules.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with breast cancer followed at the Martinique University Hospital&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 18 years of age residing in Martinique with invasive breast cancer&#xD;
             diagnosed from 2020 (single tumor at diagnosis)&#xD;
&#xD;
          -  Patients who have read the information note and have indicated that they do not wish&#xD;
             to participate in the study&#xD;
&#xD;
          -  Patient with social security coverage.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate&#xD;
&#xD;
          -  Patient with insitu breast cancer&#xD;
&#xD;
          -  Patient with a second cancer&#xD;
&#xD;
          -  Patient with cancer within 5 years prior to inclusion&#xD;
&#xD;
          -  Patient who could not answer quality of life questionnaires&#xD;
&#xD;
          -  Patient not fluent in French&#xD;
&#xD;
          -  Person under legal protection (safeguard of justice, guardianship, curators , etc.).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clarisse JOACHIM-CONTARET</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Martinique</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clarisse JOACHIM-CONTARET</last_name>
    <phone>+596596559674</phone>
    <email>clarisse.joachim@chu-martinique.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mickaelle ROSE</last_name>
    <phone>+596596592623</phone>
    <email>mickaelle.rose@chu-martinique.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Martinique</name>
      <address>
        <city>Fort-de-France</city>
        <zip>97261</zip>
        <country>Martinique</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mickaelle ROSE</last_name>
      <phone>+596596592623</phone>
      <email>mickaelle.rose@chu-martinique.fr</email>
    </contact>
    <investigator>
      <last_name>Mehdi JEAN-LAURENT</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristina FURTOS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stefanos BOUGAS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Martinique</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>June 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2021</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Survivorship</keyword>
  <keyword>Survival</keyword>
  <keyword>French West Indies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

